Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Key Products And Themes: 3Q Pharma Results Previewed

This article was originally published in Scrip

Executive Summary

Earnings season is upon us. Key motifs that will recur in pharma company briefings will include recent rhetoric on drug pricing (with pharma executive likely to emphasize how they are offering real value with innovative therapies); the threat – or for many, such as Amgen, Pfizer or Boehringer Ingelheim, the opportunity – of biosimilars given that a slew of blockbuster monoclonal antibodies are reaching or nearing loss of exclusivity; and the negative impact of currency trends on US dollar-reporting firms' sales and earnings. The perennial favorite of analyst question time, M&A intentions, will surely rear its head more than once, too.



Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts